Chromatin Modification Pathways
Organizer(s): Tony Kouzarides and Shelley L. BergerDate: March 31 - April 05, 2005
Location: Snowbird Resort, Snowbird, UT, USA
It has become apparent over the last few years that histone modifications mediate important biological functions. There is a plethora of these modifications and new ones are being discovered on a regular basis. These modifications are most commonly being studied in the context of transcriptional regulation, since classically modifications on histones were correlated with transcriptional state. However, it is now clear that any biological process involving DNA may be affected and regulated by histone modifications. As a result there are now indications that biological processes such as repair, replication and recombination are also under the control of histone modifications. Another recent development has been the mechanistic link between histone modifications and distinct processes involving nucleic acids such as DNA methylation and RNA interference. Each of these processes are under scrutiny in their own right, but the recent data suggests that each of these is intimately linked with histone modifications in the formation of heterochromatin structures which regulate transcription. Finally, data is now amassing that histone-modifying enzymes are linked to cancer. Inhibitors of deacetylases are now in phase I and II clinical trials and modifying enzymes are found over expressed, mutated and rearranged in cancer cells. The potential of these enzymes for radional drug discovery is therefore only now beginning to be realized. The aim of this meeting is to focus on basic research involving the normal biological functions relating to histone modifications and to highlight the pathways and enzymes that are deregulated in cancer cells.
Discounted Abstract Deadline: November 30 2004
Discounted Registration Deadline: January 31 2005
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Merck Research Laboratories
Sangamo BioSciences, Inc.